CardioSource WorldNews - Page 34

LIVE COURSES 2017 January 14–18 April 8 The Westin Snowmass Resort Snowmass, CO The Charleston Marriott Town Center Charleston, WV Cardiovascular Conference at Snowmass Gold Package West Virginia Chapter-ACC 12th Annual Meeting January 26–28 Cardiovascular Summit & Leadership Forum: Finance, Operations, Quality and Data Hilton Bonnet Creek Orlando, FL February 17–18 Advancing Cardiovascular Care of the Oncology Patient Park Hyatt Washington Washington, DC February 20–24 Big Sky Cardiovascular Update: Practical Applications in Clinical Cardiology Actor Portrayal The Huntley Lodge Big Sky, MT Indication Ranexa is indicated for the treatment of chronic angina. Ranexa may be used with betablockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers. IMPORTANT SAFETY INFORMATION Contraindications Ranexa is contraindicated in patients: —Taking strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, ritonavir, indinavir, and saquinavir). —Taking inducers of CYP3A (e.g., rifampin, rifabutin, rifapentine, phenobarbital, phenytoin, carbamazepine, and St John’s wort) —With liver cirrhosis Warnings and Precautions Ranexa blocks lKr and prolongs the QTc interval in a dose-related manner. Clinical experience in an acute coronary syndrome population did not show an increased risk of proarrhythmia or sudden death. However, there is little experience with high doses (> 1000 mg twice daily) or exposure, with other QTprolonging drugs, with potassium channel variants resulting in a long QT interval, in patients with a family history of (or congenital) long QT syndrome, or in patients with known acquired QT interval prolongation. Acute renal failure has been observed in patients with severe renal impairment while on Ranexa. Monitor renal function after initiation and periodically in patients with moderate to severe renal impairment. Discontinue Ranexa if acute renal failure develops. Adverse Reactions The most common adverse reactions (> 4% and more common than with placebo) during treatment with Ranexa were dizziness, headache, constipation, and nausea. Dosage and Administration Begin treatment with 500 mg twice daily and increase to the maximum recommended dose of 1000 mg twice